ATE351910T1 - Ob-fusionsprotein enthaltende zusammensetzungen und verfahren - Google Patents
Ob-fusionsprotein enthaltende zusammensetzungen und verfahrenInfo
- Publication number
- ATE351910T1 ATE351910T1 AT97952464T AT97952464T ATE351910T1 AT E351910 T1 ATE351910 T1 AT E351910T1 AT 97952464 T AT97952464 T AT 97952464T AT 97952464 T AT97952464 T AT 97952464T AT E351910 T1 ATE351910 T1 AT E351910T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- fusion protein
- methods containing
- methods
- fusion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77097396A | 1996-12-20 | 1996-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE351910T1 true ATE351910T1 (de) | 2007-02-15 |
Family
ID=25090296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97952464T ATE351910T1 (de) | 1996-12-20 | 1997-12-11 | Ob-fusionsprotein enthaltende zusammensetzungen und verfahren |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP1835030A1 (de) |
| JP (2) | JP4175668B2 (de) |
| KR (1) | KR100937550B1 (de) |
| CN (1) | CN1195858C (de) |
| AR (2) | AR009436A1 (de) |
| AT (1) | ATE351910T1 (de) |
| AU (1) | AU5606098A (de) |
| BG (1) | BG64288B1 (de) |
| BR (1) | BR9713755A (de) |
| CA (1) | CA2275183A1 (de) |
| CZ (1) | CZ298203B6 (de) |
| DE (1) | DE69737266T2 (de) |
| DK (1) | DK0954588T3 (de) |
| EA (2) | EA004790B1 (de) |
| ES (1) | ES2280083T3 (de) |
| HU (1) | HU227088B1 (de) |
| IL (1) | IL130396A (de) |
| NO (2) | NO324506B1 (de) |
| NZ (1) | NZ514145A (de) |
| PL (1) | PL194159B1 (de) |
| PT (1) | PT954588E (de) |
| RS (1) | RS49927B (de) |
| SK (1) | SK287578B6 (de) |
| WO (1) | WO1998028427A1 (de) |
| ZA (1) | ZA9711239B (de) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0866720T3 (da) * | 1995-11-22 | 2004-06-14 | Amgen Inc | OB-protein til forögelse af mager kropsmasse |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| US7074397B1 (en) | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| US6541604B1 (en) | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
| AU7132798A (en) * | 1997-04-17 | 1998-11-11 | Amgen, Inc. | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods |
| US20020019352A1 (en) * | 1997-04-17 | 2002-02-14 | David N. Brems | Stable, active, human ob protein compositions and methods |
| ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
| JP4394279B2 (ja) | 1998-03-09 | 2010-01-06 | ジーランド ファーマ アクティーゼルスカブ | 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体 |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| DK2319928T3 (da) | 1998-10-23 | 2013-06-24 | Kirin Amgen Inc | Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US6617135B1 (en) | 1999-08-09 | 2003-09-09 | Emd Lexigen Research Center Corp. | Multiple cytokine protein complexes |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| DK1252192T3 (da) | 2000-02-11 | 2006-11-20 | Merck Patent Gmbh | Forbedring af antistofbaserede fusionsproteiners serumhalveringstid |
| WO2001081377A2 (en) * | 2000-04-21 | 2001-11-01 | Amgen, Inc. | Integrin/adhesion antagonists |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| US20020090646A1 (en) * | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
| RU2272644C2 (ru) | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
| WO2002069232A2 (en) | 2001-02-19 | 2002-09-06 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| KR100900176B1 (ko) | 2001-03-07 | 2009-06-02 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술 |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| JP2002306163A (ja) * | 2001-04-11 | 2002-10-22 | Chemo Sero Therapeut Res Inst | 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法 |
| CA2446087C (en) | 2001-05-03 | 2013-06-18 | Stephen D. Gillies | Recombinant tumor specific antibody and use thereof |
| AU2002359288B2 (en) | 2001-10-22 | 2008-07-31 | Amgen, Inc. | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| BR0214650A (pt) | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| JP4494977B2 (ja) | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質 |
| JP3936673B2 (ja) * | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| DK1699822T3 (da) | 2003-12-30 | 2008-08-04 | Merck Patent Gmbh | IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf |
| EA011859B9 (ru) | 2004-01-05 | 2013-07-30 | Емд Лексиген Ресерч Сентер Корп. | Соединения для адресной доставки препарата к ткани или органу-мишени |
| US8603969B2 (en) | 2004-02-11 | 2013-12-10 | Amylin Pharmaceuticals, Llc | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| CA2572765C (en) | 2004-07-08 | 2013-05-21 | Amgen Inc. | Compound having improved bioefficiency when administered in a multidose regimen |
| DK1773884T3 (da) | 2004-08-03 | 2012-05-21 | Innate Pharma | Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor |
| CN101103045B (zh) | 2004-09-24 | 2015-11-25 | 安姆根有限公司 | 修饰的Fc分子 |
| ES2325773T5 (es) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Tratamiento de la obesidad y de los trastornos relacionados |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| ATE465176T1 (de) | 2004-12-09 | 2010-05-15 | Merck Patent Gmbh | Il-7-varianten mit reduzierter immunogenität |
| JP2009504681A (ja) * | 2005-08-11 | 2009-02-05 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 選択可能な特性を有するハイブリッドポリペプチド |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| WO2007045465A1 (en) | 2005-10-21 | 2007-04-26 | F. Hoffmann-La Roche Ag | Method for the recombinant expression of a polypeptide |
| TW200738752A (en) | 2006-01-31 | 2007-10-16 | Bayer Schering Pharma Ag | Modulation of MDL-1 activity for treatment of inflammatory disease |
| US8501686B2 (en) | 2008-06-05 | 2013-08-06 | University Of Michigan | Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects |
| CA2759333A1 (en) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
| NZ714757A (en) | 2009-08-14 | 2018-07-27 | Us Gov Health & Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| PT2621515T (pt) | 2010-09-28 | 2017-07-12 | Aegerion Pharmaceuticals Inc | Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada |
| US20140256621A1 (en) | 2011-07-08 | 2014-09-11 | Astrazeneca Pharmaceuticals Lp | Engineered poypeptides having enhanced duration of action and reduced immunogenicity |
| DK2764565T3 (da) | 2011-10-05 | 2023-04-17 | Oned Mat Inc | Aktive siliciumnanostrukturmaterialer til lithiumionbatterier og fremgangsmåder, sammensætninger, komponenter og anordninger i forbindelser dermed |
| HUE040496T2 (hu) | 2012-09-27 | 2019-03-28 | Childrens Medical Ct Corp | Vegyületek elhízás kezelésére és alkalmazási eljárásaik |
| SI3074033T1 (sl) | 2013-11-26 | 2019-03-29 | The Children's Medical Center Corporation | Spojine za zdravljenje debelosti in postopki njihove uporabe |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| PL3509624T3 (pl) | 2016-09-12 | 2024-03-25 | Amryt Pharmaceuticals Inc. | Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie |
| CN110396133B (zh) | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| CN110183530A (zh) | 2019-06-21 | 2019-08-30 | 深圳市亚辉龙生物科技股份有限公司 | 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用 |
| CN112618698B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白的注射制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| CA2196200A1 (en) * | 1994-07-29 | 1996-02-15 | Michael Joseph Browne | Novel compounds |
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| JPH0870875A (ja) * | 1994-09-05 | 1996-03-19 | Tosoh Corp | 組換えアルカリフォスファタ−ゼ融合タンパク質 |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| DK0866720T3 (da) * | 1995-11-22 | 2004-06-14 | Amgen Inc | OB-protein til forögelse af mager kropsmasse |
| CA2238307A1 (en) * | 1995-12-27 | 1997-07-10 | Genentech, Inc. | Ob protein derivatives having prolonged half-life |
-
1997
- 1997-12-11 AT AT97952464T patent/ATE351910T1/de active
- 1997-12-11 ES ES97952464T patent/ES2280083T3/es not_active Expired - Lifetime
- 1997-12-11 JP JP52889698A patent/JP4175668B2/ja not_active Expired - Fee Related
- 1997-12-11 EA EA199900575A patent/EA004790B1/ru not_active IP Right Cessation
- 1997-12-11 NZ NZ514145A patent/NZ514145A/en not_active IP Right Cessation
- 1997-12-11 EP EP06024946A patent/EP1835030A1/de not_active Withdrawn
- 1997-12-11 RS YUP-279/99A patent/RS49927B/sr unknown
- 1997-12-11 CZ CZ0203699A patent/CZ298203B6/cs not_active IP Right Cessation
- 1997-12-11 DE DE69737266T patent/DE69737266T2/de not_active Expired - Lifetime
- 1997-12-11 CN CNB971818177A patent/CN1195858C/zh not_active Expired - Fee Related
- 1997-12-11 BR BR9713755-3A patent/BR9713755A/pt active Search and Examination
- 1997-12-11 PL PL334242A patent/PL194159B1/pl not_active IP Right Cessation
- 1997-12-11 EP EP97952464A patent/EP0954588B1/de not_active Expired - Lifetime
- 1997-12-11 HU HU0000302A patent/HU227088B1/hu not_active IP Right Cessation
- 1997-12-11 PT PT97952464T patent/PT954588E/pt unknown
- 1997-12-11 KR KR1019997005618A patent/KR100937550B1/ko not_active Expired - Fee Related
- 1997-12-11 WO PCT/US1997/023183 patent/WO1998028427A1/en not_active Ceased
- 1997-12-11 DK DK97952464T patent/DK0954588T3/da active
- 1997-12-11 AU AU56060/98A patent/AU5606098A/en not_active Abandoned
- 1997-12-11 EA EA200100216A patent/EA004791B1/ru not_active IP Right Cessation
- 1997-12-11 CA CA002275183A patent/CA2275183A1/en not_active Abandoned
- 1997-12-11 IL IL130396A patent/IL130396A/en not_active IP Right Cessation
- 1997-12-11 SK SK774-99A patent/SK287578B6/sk not_active IP Right Cessation
- 1997-12-15 ZA ZA9711239A patent/ZA9711239B/xx unknown
- 1997-12-16 AR ARP970105894A patent/AR009436A1/es active IP Right Grant
-
1999
- 1999-06-08 NO NO19992779A patent/NO324506B1/no not_active IP Right Cessation
- 1999-06-23 BG BG103522A patent/BG64288B1/bg unknown
-
2007
- 2007-03-16 NO NO20071415A patent/NO325096B1/no not_active IP Right Cessation
- 2007-03-16 AR ARP070101065A patent/AR059907A2/es unknown
-
2008
- 2008-05-29 JP JP2008140707A patent/JP4659068B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE351910T1 (de) | Ob-fusionsprotein enthaltende zusammensetzungen und verfahren | |
| DE69834401D1 (de) | Businterfacesystem und verfahren | |
| DE69607321D1 (de) | Reinigungsverfahren und zusammensetzung | |
| NO991676D0 (no) | FremgangsmÕter og sammensetninger for immunmodulering | |
| EP0918787A4 (de) | Zusammensetzungen und methoden zur gegenstrang-hemmung der proteinübersetzung | |
| NO20003096D0 (no) | Sammensetninger og fremgangsmÕter for behandling av ADD | |
| BR9509732A (pt) | Composição de limpeza e método de usá-la | |
| EP1006796A4 (de) | Zusammensetzungen und verfahren zur applikation von borrelia dna | |
| FI943745L (fi) | Koostumuksia ja menetelmiä proteiinin rakenteen määrityksiin | |
| EP1014995A4 (de) | Zusammensetzungen und verfahren zur verhütung von restenosis nach wiedergefässbildung | |
| ZA964733B (en) | Ob protein compositions and methods | |
| DE69534416T2 (de) | Verfahren und formulierungen zur bekämpfung von schadinsekten | |
| DE69517683D1 (de) | Alpha-galactosyl-epitope enthaltende zusammensetzungen und verfahren für impfstoffe | |
| DE69822873D1 (de) | Zusammensetzungen und verfahren zur gewichtsverringerung | |
| DE69918842D1 (de) | Desinfektionszusammensetzungen und verfahren | |
| EP0883674A4 (de) | Desinfizierende zusammensetzungen und verfahren zur desinfektion von oberflachen | |
| DE69714504D1 (de) | Benzothiopene, diese enthaltende Zubereitungen und Verfahren | |
| DE69620642D1 (de) | Reiningungsverfahren und-zusammensetzung | |
| DE19782204T1 (de) | Verlängerungseinrichtung und Verfahren | |
| DE69919340D1 (de) | Überzugszusammensetzungen und verfahren | |
| DE69924489D1 (de) | Getreide-beta-glukanzusammensetzungen und verfahren | |
| ATE242600T1 (de) | Synergitische herbizide verfahren und zusammensetzungen | |
| EP1073333A4 (de) | S-rabeprazol enthaltende zusammensetzungen und verfahren | |
| DE69526946D1 (de) | Aktivierte tonzusammensetzung und verfahren | |
| DE69718502D1 (de) | Zahnärztliche zusammensetzung, system und verfahren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0954588 Country of ref document: EP |